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Regional correlation of biochemical
measures of amyloid and tau phosphorylation
in the brain
Kanta Horie1, Nicolas R. Barthélemy1*, Nipun Mallipeddi1, Yan Li2, Erin E. Franklin3,5, Richard J. Perrin1,3,4,5,
Randall J. Bateman1,4,5 and Chihiro Sato1*

Abstract
Alzheimer’s disease (AD) neuropathologic change is characterized by amyloid plaques and neurofibrillary tangles
(NFTs) that consist of aggregated amyloid beta (Abeta) and hyperphosphorylated tau proteins (p-tau), respectively.
Although the global relationship between Abeta and p-tau has been studied for decades, it is still unclear whether a
regional correlation exists between Abeta and p-tau in the human brain. Recent studies in cerebrospinal fluid (CSF)
have suggested that tau phosphorylation at specific sites such as T217 is modified at an early stage of AD when
amyloid plaques become detectable. We applied biochemical and mass spectrometry methods in human brain samples with and without Abeta plaque pathology to measure site-specific phosphorylation occupancies in soluble and
insoluble tau. Our quantitative results identified multiple residues specifically hyper-phosphorylated in AD, including
at sites T111, T153, S184 (or S185), T205, S208, T217, S262, and S285 in brain soluble tau. In contrast, the most enriched
phosphorylated residues in brain insoluble tau were T111, S113, T153, T181, S199, S202, T205, T217, T231, S262, and
S396. Tau phosphorylation occupancies in the insoluble fraction were relatively constant across brain regions, suggesting that tau has a consistent phosphorylation pattern once it has aggregated into NFTs. We did not find regional
association between Abeta42 and insoluble tau. However, the phosphorylation profile of soluble tau in AD brain was
highly correlated to that in AD CSF, which was analyzed in a previous study. We also found a higher regional association between total Abeta42 and soluble tau phosphorylation occupancy at residues T111, T153 and T217 in the brain.
This study provides insights into regional interactions between amyloidosis and specific tau phosphorylated residues
in the human brain and may explain the specific increases of tau species phosphorylation observed in AD CSF.

Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that affects stereotyped regions of the
brain and, over many years, leads to synaptic impairment and neurological decline. The neuropathological
hallmarks of AD are amyloid plaques that accumulate
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early in AD, and neurofibrillary tangles (NFTs) that
accumulate later and correlate more closely with clinical impairment. Plaques and NFTs are composed of
aggregated amyloid beta (Abeta) and hyperphosphorylated tau (p-tau), respectively. A potential link and
causality between Abeta and p-tau has been studied
over two decades. The ‘Amyloid hypothesis’ suggests
that Abeta primarily drives AD pathogenesis and that
tau hyperphosphorylation, aggregation, and formation of NFTs occur downstream. However, it is still
unknown whether there is a direct link between Abeta
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and tau hyperphosphorylation, especially on a local
level in the human brain.
Recent in vivo analyses of cerebrospinal fluid (CSF)
from familial AD mutation carriers have shown a close
association between changes in aggregated Abeta
and tau phosphorylation occupancy at specific sites
[2]. Hyperphosphorylation at residue T217 increases
almost simultaneously with Abeta deposition, as measured by positron emission tomography (PET), more
than 20 years before symptoms onset. Other phosphorylated residues such as T181 and T205 change later in
the disease trajectory, suggesting that tau phosphorylation sites are differently affected by metabolic changes
subsequent to amyloidosis. Notably, all these modifications occur before the detection of tau aggregation
measured by PET, concomitantly with the increase in
cognitive symptoms [23], suggesting that hyperphosphorylation of CSF soluble tau occurs before substantial NFT formation. However, little is known about site
specific changes in tau phosphorylation in AD brain
and how it translates to CSF.
Prior work suggests high concordance between PET
and CSF biomarkers for Abeta pathology [8, 33] and
modest concordance between PET and CSF for tau
pathology [5, 6, 14]. Such comparisons are somewhat
awkward, as they relate global levels of CSF analytes
to a summary of regional measures of PET. To find a
direct link between Abeta and p-tau and address how
local concentrations of Abeta and different p-tau species may be associated in the human brain, biochemical
methods that can measure both Abeta and p-tau in the
same brain tissue will be necessary. Given that soluble
tau species found in CSF likely reflect soluble tau in the
brain, investigating tau in brain soluble fraction would
be critical. Although hyperphosphorylation sites of tau
have been previously qualitatively studied in insoluble
fractions in AD [16–18], quantitation of phosphorylation occupancy has never been annotated, especially in
soluble fractions.
In this study, we biochemically analyzed multiple
regions from human brains with and without AD neuropathologic change (ADNC) to measure local Abeta
and p-tau correlation in soluble and insoluble fractions.
Results from this study may provide evidence for a
direct link between local Abeta and tau phosphorylation in AD. Furthermore, we combined sensitive mass
spectrometry (MS) methods to extensively profile and
quantitate over 20 soluble and insoluble p-tau species in human brain samples. This may provide critical
insights into the interpretation of how different CSF
p-tau biomarkers dynamically change in quantity and
stoichiometry in AD.
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Materials and methods
Human brain samples

Frozen postmortem brain tissue samples from cases representing different stages of ADNC were obtained from
the Knight ADRC Neuropathology Core at Washington
University School of Medicine. ADNC was classified
according to National Institute on Aging and Alzheimer’s
Association criteria [24], using data from immunohistochemistry (10D5 and PHF-1 primary antibodies) applied
to formalin-fixed, paraffin-embedded tissue samples
from the left side of each brain. In the first cohort, the
two cases selected to represent “controls” lacked evidence of parenchymal amyloid and showed modest NFT
pathology typical of older neuropathologic cohorts (Thal
Abeta phase 0, Braak NFT stage II). Two cases selected
to represent “early stage” AD pathology showed intermediate-to-high distributions of diffuse amyloid plaques
and modest NFT pathology (these cases were: Thal Abeta
phase 3, Braak NFT stage I; and Thal Abeta phase 4,
Braak NFT stage II). Two cases selected to represent “late
stage” AD were: Thal Abeta phase 4, Braak NFT stage
V; and Thal Abeta phase 5, Braak NFT stage VI. Frozen
samples from the right side of each brain were collected
from 10 to 11 regions, including cerebellum (CB), superior frontal gyrus (SFG), frontal pole (FP), superior temporal gyrus (Temp), occipital lobe (Ocp), thalamus (Thal),
amygdala (Amy), midbrain (Mid), pons, inferior parietal
lobule (Pari), and Striatum. In the second cohort, parietal region from 20 participants with various amyloid and
tau pathologies were analyzed. The study was approved
by the Washington University in St. Louis Institutional
Review Board, and all participants were consented for
autopsy and sharing of samples.
Fractionation of brain samples

The protocol for brain sample fractionation is described
in Additional file 1: Fig. S1. Frozen brain tissue was sliced
using a cryostat at − 20 °C, weighed, collected in tubes,
and stored at − 80 °C prior to biochemical analyses. The
tissue (300–400 mg) was sonicated in ice-cold buffer
containing 25 mM tris-hydrochloride (pH 7.4), 150 mM
sodium chloride, 10 mM ethylenediaminetetraacetic
acid, 10 mM ethylene glycol tetraacetic acid, phosphatase
inhibitor cocktail (Sigma), and protease inhibitor cocktail
(Roche). Final brain tissue suspension was at a concentration of 0.3 mg/μL buffer. The tissue suspension was clarified by centrifugation for 20 min at 11,000 g at 4 °C, and
the resulting supernatant was defined as “brain homogenate,” which was used for brain total (soluble + insoluble)
Abeta and soluble tau analysis. For insoluble tau analysis, the brain homogenate was incubated with 1% sarkosyl for 60 min on ice, followed by ultra-centrifugation at
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100,000 g at 4 °C for 60 min to obtain an insoluble pellet,
which was defined as “brain insoluble extract” and used
for brain insoluble tau analysis.
Biochemical analysis of amyloid by MS

Brain homogenate (50 μL) containing total (soluble + insoluble) Abeta was mixed with 450 μL of phosphate-buffered saline (PBS) pH 7.4 containing 1% bovine
serum albumin and 20 μL of solution containing 15N
Abeta40 and 42 uniformly labeled (0.25 and 0.025 ng/
µL, respectively. rPeptide) as an internal standard. Abeta
was immunoprecipitated with HJ5.1 antibody (antiAbeta13–28 mid domain) beads (30 μL, 3 mg/mL), then
the bound Abeta was digested on-beads with 50 μL of
LysN (0.25 ng/μL) in 25 mM triethyl ammonium bicarbonate (TEABC). Digests were desalted by C18 TopTip.
Before eluting samples, 3% hydrogen peroxide and 3%
formic acid (FA) in water was added onto the beads, followed by overnight incubation at 4 °C to oxidize the peptides containing methionine. The eluent was lyophilized
and resuspended in 25 µL of 10% FA and 10% acetonitrile and 20 nM BSA tryptic digest prior to MS analysis
on nanoAcquity UPLC system (Waters) coupled to Xevo
TQ-S mass spectrometer (Waters) operating in selected
reaction mode. Abeta40 and 42 peptides were quantified
by MS.
Insoluble tau analysis by MS

Brain insoluble extract was resuspended with 200 μL of
PBS followed by sonication. The resulting suspension
(10–20 μL containing 2.5 μg of total protein) was mixed
with 200 μL of lysis buffer (7 M urea, 2 M thio-urea, 3%
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 1.5% n-octyl glucoside, 100 mM
TEABC) followed by spiking with 5 μL of solution containing 15N Tau-441 (2N4R) uniformly labeled (2 ng/
µL, gift from Dr. Guy Lippens, Lille University, France)
as an internal standard. Five μL of 500 mM dithiothreitol was added to the suspension, followed by sonication.
The resulting solution was mixed with 15 μL of 500 mM
iodoacetamide and incubated for 30 min at room temperature in the dark.
Protein digestion was conducted using the filter-aided
sample preparation method as previously reported [25].
Briefly, each prepared solution was loaded on a Nanosep
10 K filter unit (PALL) and centrifuged. After washing
the sample on the filter unit with 8 M urea in 100 mM
TEABC solution, immobilized proteins were digested on
the filter using endoproteinase Lys-C at 37 °C for 60 min.
Then, the samples were further digested using trypsin at
37 °C overnight. The digested samples were collected by
centrifugation, then desalted by C18 TopTip. In this purification process, 50 fmol each of AQUA internal-standard
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peptide was spiked for the quantification of some specific
peptides. Before eluting samples, 3% hydrogen peroxide
and 3% FA in water was added onto TopTip, followed by
overnight incubation at 4 °C to oxidize the peptides containing methionine residues. The eluent was lyophilized
and resuspended in 27.5 µL of 2% acetonitrile and 0.1%
FA in water prior to MS analysis on nanoAcquity UPLC
system coupled to Orbitrap Fusion Tribrid or Orbitrap
Eclipse Tribrid mass spectrometer (Thermo Scientific)
operating in PRM mode. Forty-eight brain tau peptides
including 26 phosphorylation sites were measured within
the insoluble tau fraction (Additional file 1: Table S1).
Soluble tau analysis by MS

Brain homogenate (50 μL) was mixed with 450 μL of PBS
and 10 μL of solution containing 15N Tau-441 (2N4R)
uniformly labeled (200 pg/µL) as an internal standard.
Brain tau isoforms were immunoprecipitated with N-terminal HJ8.5 and mid-domain Tau1 antibodies. Immunoprecipitated tau isoforms were processed and digested as
described previously [26]. The same MS methods were
used as described above in insoluble tau analysis section.
Quantitative assessment of phosphorylation occupancy
of tau

To assess the phosphorylation occupancy of specific sites
in tau from brain homogenates and insoluble extracts, we
measured the extent of phosphorylation on each site as
described previously [3]. Briefly, two methods were used
for this purpose: (1) phosphorylated peptides were normalized with the non-phosphorylated peptide as reference. MS/MS transition specific to each phosphorylated
peptide was compared to the corresponding transition
from the non-phosphorylated peptide; (2) absolute quantitation using internal synthetic labeled standards (i.e.,
AQUA peptides) for each phosphorylated and nonphosphorylated peptide. Signals from phosphorylated
and non-phosphorylated standards were used to define
an internal ratio. Because of the limited availability of
AQUA peptides, a defined set of phosphorylated sites
were assessed using AQUA peptides (i.e., T175, T181,
S199, S202, T205, T217, T231, and S404).

Results
Biochemical quantitation of regional brain Abeta
deposition

In the first cohort, two brains each were selected to represent control (“control”, without Abeta, and with minimal NFT pathology), early stages of ADNC (“Abeta+”,
intermediate-to-high Abeta pathology and minimal
NFT pathology), and late stages of ADNC (“AD’’ with
advanced Abeta and NFT pathologies) (Table 1). For each
case, 10 to 11 brain regions were sampled to include areas
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Table 1 Sample demographics and neuropathological annotations in first cohort
Brains

Control

Abeta+

AD

Participant number

#1

#2

#3

#4

#5

#6

NIA-AA score

A0B1

A0B1

A3B1

A2B1

A3B3

A3B3

Age at death

80

87

90

72

85

81

Sex

Male

Male

Male

Male

Male

Female

ApoE genotype

ε3/ε3

ε3/ε3

ε3/ε3

ε3/ε4

ε3/ε3

ε3/ε3

PMI (h)

7

47

14.5

33.3

16.3

12

NIA-AA score incorporates histopathologic assessments of Abeta deposits (A), and staging of NFTs (B) [24]. ApoE: Apolipoprotein E. PMI: postmortem interval between
time of death and freezing (and beginning of fixation by immersion in formalin) of brain tissue

expected to harbor a broad range of amyloid plaque and
NFT burdens. This cohort was used to test the hypothesis that there are regional correlations between Abeta
and specific tau species. In the second cohort, parietal
region from 20 participants with various Abeta and tau
pathologies were analyzed (Additional file 1: Table S2).
This cohort was used to confirm the results from the
first cohort in one brain region across a larger number of
participants.
For each brain sample, we measured Abeta40 and 42
concentrations in corresponding brain homogenate containing both soluble and insoluble Abeta using immunoprecipitation (IP) followed by MS analysis (Additional
file 1: Fig. S1). While the Abeta40 measures did not correlate with the neuropathological annotations in the
second cohort samples, the Abeta42 measures were generally consistent with the neuropathological annotations
(Additional file 1: Table S2), suggesting that total Abeta42
can be used as a surrogate of amyloid load. In addition,
the Abeta40 concentrations were lower or equal to the
Abeta42 concentrations, supporting that the Abeta species measured in this study are primarily derived from
insoluble aggregates.
In the first cohort, control cases (#1 and #2) had no
quantifiable Abeta42 in homogenates from most brain
areas (Fig. 1). Most brain region homogenates from AD
cases had substantial amounts Abeta (SFG, FP, Temp,
Ocp, Thal, Amy, Pari and Striatum). “Abeta+” brains (#3
and #4) showed intermediate Abeta42 concentrations
in Ocp. The cerebellum, midbrain and pons showed less
Abeta42 than the other regions, consistent with previous
reports [19]. We note, however, that #4 had much higher
Abeta42 concentration in Temp and Amy regions than
#3; these differences may reflect Apolipoprotein E (ApoE)
genotypes (i.e., #4 is ε3/ε4 carrier, Table 1), inherent variability or hemispheric asymmetry in early-stage ADNC
(frozen samples are from the right hemibrain; ADNC
classification was performed on the left), variations in
dissection of these brain regions from case to case, and/
or the potential disconnect between Thal phase (which

Fig. 1 Heat map of Abeta42 concentration across different brain
regions. Nine–eleven brain regions from six participants with different
stages of ADNC (NIA-AA stages A0–A3 for amyloid deposition derived
from Thal Abeta phases 0-5, and stages B0–B3 for Braak NFT stages
0-VI) were analyzed for Abeta42. Soluble and insoluble Abeta42
concentrations (ng/g of tissue) in brain homogenate are summarized.
The data below limit of quantification (1.2 ng/g of tissue) are
described as “< 1.2”. Gray: tissue was not available

describes anatomic distributions of amyloid plaques)
and amyloid plaque density/burden, which is generally
reflected by but does not directly contribute to determination of Thal phase.
Relationship between brain MTBR‑tau enrichment
and Abeta

A series of recent cryogenic electron microscopy (CryoEM) studies demonstrated that the core structure of
tau aggregates consists of a sub-segment of the microtubule binding region (MTBR) domain and the particular conformation depends on the tauopathy [9, 10, 12,
34]. Additionally, specific enrichment of MTBR peptides
over other tau peptides has been described in AD insoluble tau fraction [21, 25]. Therefore, we first quantified
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MTBR-tau in AD, Abeta+, and control brains in the
first cohort to examine if MTBR-tau recapitulates tau
pathology. The quantitation of 14 unmodified tau peptides in brain insoluble extracts confirmed that tau species containing upstream of MTBR domain (residues
243-254: MTBR-tau-243) and repeat region 2 (R2) to R3
and R4 (residues 299-317: MTBR-tau-299 and residues
354-369: MTBR-tau-354, respectively) were specifically
enriched in AD compared to Abeta+ and control cases
(2- to 4-fold difference in magnitude. Figure 2). This suggests that these insoluble MTBR-tau species recapitulate
tau pathology annotated using immunohistochemistry
in AD. In comparison, soluble tau from all brain extracts
exhibited a profile consistent with full length tau as previously reported [26].
Next, we investigated if Abeta42 concentrations correlate with tau pathology measured by insoluble MTBR-tau
species. There were low correlations between Abeta42
and insoluble MTBR-tau isoforms across brain regions
in the first cohort (Spearman r = − 0.12, r = − 0.15, and
r = − 0.03 for MTBR-tau-243, 299, and 354, respectively.
Additional file 1: Fig. S2). However, the second cohort
showed non-linear correlations consisting of two phases

10

Control
Abeta+

Peptide / 181-190

8

AD
6
4
2

396-406

386-395

354-369

299-317

275-280

260-267

243-254

226-230

195-209

68-87

151-155

45-67

6-23

25-44

0

Residues
Fig. 2 MTBR-tau is enriched in AD brain insoluble extracts in the first
cohort. Enrichment profile of MTBR-tau peptides in insoluble extracts
from AD (n = 15; seven or eight brain regions from two participants),
Abeta+ (n = 14; seven brain regions from two participants), and
control brains (n = 12; six brain regions from two participants)
were analyzed by mass spectrometry. Relative abundance of tau
peptides was quantified relative to mid-domain (residue 181-190)
peptide for internal normalization. MTBR-tau-243 (residue 243-254),
MTBR-tau-299 (residues 299-317), and MTBR-tau-354 (residues
354-369) were highly enriched in the AD brains compared to Abeta+
and controls. MTBR-tau-299 and MTBR-tau-354 are located inside the
filament core of AD aggregates [12]. Unmodified residues 195-209
decreased in AD brains, potentially due to a higher phosphorylation
in AD. Data are represented as mean ± SEM

(Additional file 1: Fig. S3), which may be driven by a high
number of amyloid-negative participants in the second
cohort (n = 8), compared to only two cerebellum samples
with no amyloid pathology in the first cohort. Nevertheless, in both cohorts, once the Abeta42 level exceeded a
threshold, MTBR-tau increased in AD independently
from local Abeta burden.
P‑tau profiles in soluble and insoluble brain fractions in AD

Previously, we developed sensitive quantitative MS methods to extensively analyze p-tau species, and annotated
over 20 phosphorylation sites in the CSF from individuals
with AD [3]. In this study, we hypothesized that changes
in p-tau species are translated from brain soluble fraction
to CSF, and extensively profiled p-tau species comparing insoluble and soluble brain fractions from individuals
with AD. Results of MS quantification are summarized
in Fig. 3, Additional file 1: Table S1, and Additional file 1:
Fig. S4.
In AD insoluble brain fractions, 14 phosphorylated
sites were quantified and 11 showed pronounced increase
of phosphorylation occupancy compared to control and
AD soluble fractions. The list of enriched phosphorylated
residues included T111, S113, T153, T181, S199, S202,
T205, T217, T231, S262, and S396.
In soluble brain fractions, 22 and 26 phosphorylated
sites were quantified in control and AD brains, respectively. We identified a pronounced increase of the phosphorylation occupancy on residues T111, T175, S184/
S185 (undetermined position), T217 and S262 and new
phosphorylation of residues T153, T205, S208 and S285
in AD brain soluble fraction.
We also searched for multiply phosphorylated tau peptides that would correspond to phosphorylated epitopes
used for neuropathological studies (i.e., AT8 and PHF1.
Additional file 1: Fig. S5) [22]. These multiply phosphorylated tau peptides were only identified in AD fractions
likely due to low tau recovery from the control brain
fractions, except for PHF1 (pS396 + pS404), which were
identified in both control and AD soluble fractions. We
also found a complex pattern of co-eluted, doubly-phosphorylated peptides for the 195-210 sequence, which differed significantly between control and AD brain extracts.
After careful interpretation of LC–MS/MS signals, we
attribute this differential pattern to pT205 and pS208.
Phosphorylation at T205 or S208, combined with more
abundant pS198, pS199 or pS202, led to these AD-associated doubly-phosphorylated peptide signals. We further
observed triple phosphorylation pattern on the 195-210
peptide, but signals were too low to confidently identify
the phosphorylated residues involved. This combination
of phosphorylation sites could include the AT8 epitope
(pS202 + pT205 + pS208). Notably, differential analysis of
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Fig. 3 Mapping tau phosphorylation in AD brain soluble and insoluble fractions compared to CSF. Schematics of tau phosphorylation
occupancies in AD CSF and brain. Tau phosphorylation occupancies in the control (a) and AD (b) CSF [3]. CSF tau is truncated after mid domain.
Tau phosphorylation occupancies in control (c), AD soluble (d) and insoluble (e) brain fractions. T111, T153, S205 T175, S184 (or S185), S208, T217,
S262, S285 are hyperphosphorylated (AD/control fold ratio > 2) in AD brain soluble tau (from brain homogenate). Phosphorylation occupancies at
T111(0N), S113 (0N), T153, T181, S199, S202, T205, T217, T231, S262 and S396 are particularly increased in AD insoluble brain fractions and show a
change according to the disease progression

AD brain extracts before and after high speed centrifugation showed a decrease in the final supernatant of peptides phosphorylated at T205 and S208, suggesting their
propensity for sedimentation (Additional file 1: Fig. S6).
Local relationship between p‑tau species and Abeta in AD
brain

First, to test the hypothesis that local Abeta pathology
correlates with specific p-tau species and tau aggregation in AD, we evaluated AD brain insoluble fractions
for associations between Abeta and selected p-tau with
the highest hyperphosphorylation rates (pT181, pS202,
pT217, and pT231).
In the first cohort, across the brain regions, the phosphorylation occupancy of each tau species was highly
correlated with Abeta load (Spearman r = 0.55, r = 0.76,
r = 0.78, and r = 0.89 for pT181, pS202, pT217, and
pT231, respectively. Figure 4), suggesting that the specific p-tau species in AD NFTs may correlate regionally with local Abeta42 concentration. However, these
correlations are primarily driven by the few data points
from cerebellum where amyloid pathology and p-tau are
both low. Indeed, the correlations between these p-tau
species and Abeta may be modeled bimodally, with a
very steep increase at low Abeta42 levels followed by

plateauing of phosphorylation occupancies (i.e., exponential plateau curve fitting: 
R2 = 0.90 plateauing at
28% of phosphorylation occupancy, 0.82 plateauing
at 51%, 0.82 plateauing at 31%, and 0.98 plateauing at
82% for pT181, pS202, pT217, and pT231, respectively).
This latter model suggests that tau phosphorylation in
AD NFTs are not directly associated with amyloid after
an initial increase in Abeta and p-tau. In other words,
an early increase in Abeta42 may be permissive for tau
phosphorylation at these sites, but further increases in
Abeta42 do not potentiate greater tau hyperphosphorylation in insoluble fraction. In the second cohort, the
same correlations were confirmed except for pS202,
which showed less correlation with Abeta42 (Spearman
r = 0.14. Additional file 1: Fig. S7). This discrepancy
may be due to the amyloid-negative group (n = 8) in the
second cohort having higher concentrations of Abeta42
(7.6 ± 2.1 (SEM) ng/g of tissue) than the amyloid-negative cerebellum and pons samples in the first cohort
(≤ 3.8 ng/g of tissue). This slightly high level of Abeta42
may be sufficient to induce the hyperphosphorylation
of the residue S202 in insoluble fraction. Alternatively,
parietal regions used in the second cohort may respond
differently in the context of AD compared to cerebellum and pons analyzed in the first cohort.
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Fig. 4 Phosphorylation occupancies of insoluble pT181, pS202, pT217, and pT231 have non-linear correlations with Abeta42 concentrations in
AD brain. The phosphorylation occupancies of a pT181, b pS202, c pT217, and d pT231 in brain insoluble extracts showed non-linear correlations
with soluble and insoluble Abeta42 concentrations ( R2 = 0.90, R2 = 0.82, R2 = 0.82, and R2 = 0.98, respectively, in exponential-plateau model).
Spearman r = 0.55, r = 0.76, r = 0.78, and r = 0.89 for pT181, pS202, pT217, and pT231, respectively. A total of 15 brain insoluble extracts from two
AD participants (#5: blue, #6: red) were analyzed (regions: CB, SFG, Temp, Ocp, Amy, Pari, and Striatum from #5; CB, SFG, Temp, Ocp, Amy, Pons, Pari,
and Striatum from #6). Two measures of pT217 from CB, one pT217 from Pons, and one pS202 from CB were below the detection limit and 0%
were utilized in these data for modeling. Regression curves depict an exponential plateau model. Open data points indicate data from CB regions
containing low amyloid pathology

Next, we investigated correlations between Abeta42
and these same p-tau species (pT181, pS202, pT217,
and pT231) in soluble extracts from AD brains. In the
first cohort, interestingly, pS202 and pT231 phosphorylation occupancies in soluble extracts showed weaker
correlations with Abeta42 concentrations (Spearman
r = 0.54 and r = 0.54 for pS202 and pT231, respectively.
Figure 5e, f ) compared to the insoluble extracts, suggesting that insoluble pS202 and pT231 are more associated with Abeta42 than soluble forms. In contrast,

pT181 and pT217 in soluble fractions were more highly
correlated with Abeta42 (Spearman r = 0.70, and 0.88,
respectively. Figure 5c, d) than pT181 and pT217 were in
insoluble fractions. We also examined additional p-tau
species pT111 and pT153 that were only detected in
soluble fractions attributed to higher MS sensitivity in
soluble fractions (Fig. 5a, b). These two emerging p-tau
species were also correlated with Abeta42 in soluble fractions to the same degree as pT217 (Spearman r = 0.90
and 0.85, respectively). Phosphorylation occupancies in
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Fig. 5 Phosphorylation occupancies of select soluble p-tau is highly and linearly correlated with Abeta42 concentrations in AD brain from the first
cohort. The phosphorylation occupancies of a pT111 (0N), b pT153, c pT181, and d pT217 in brain soluble extracts showed correlations with soluble
Abeta42 (Spearman r = 0.90, r = 0.85, r = 0.70, and r = 0.88, respectively). In contrast, phosphorylation at e pS202 and f pT231 were more-weakly
correlated with Abeta42 (Spearman r = 0.54 and r = 0.54, respectively). A total of 19 brain soluble extracts from two AD participants (#5: blue,
#6: red) were analyzed (regions: CB, SFG, FP, Temp, Ocp, Thal, Amy, Pons, Pari, and Striatum from #5; CB, SFG, Temp, Ocp, Thal, Amy, Pons, Pari, and
Striatum from #6). Open data points indicate data from CB regions containing low amyloid pathology
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Next, we analyzed brain fractions from “Abeta+” cases
with intermediate to high Abeta pathology and minimal
NFT burden to explore whether early stage ADNC shows
an intermediate correlation between Abeta and p-tau.
Indeed, soluble pT111, pT153, and pT217, which are
well correlated with Abeta42 (Spearman r > 0.7), showed
staged elevations of phosphorylation occupancies from
control to Abeta+ to AD brains in the first cohort (Fig. 6).
These findings suggest that an increase in soluble p-tau at
T111, T153, and T217 can occur as early as Braak NFT
stage I in multiple brain areas, including areas without
evidence of regional NFT pathology (by PHF-1 immunohistochemistry). The elevations of phosphorylation
occupancies according to the disease progression were
also confirmed in the second cohort, which showed
similar staged increases across groups (amyloid negative,
very mild to moderate AD, severe AD) for soluble pT111,
pT153, and pT217, but not for pT181 (Additional file 1:
Fig. S9).
We observed that the phosphorylation occupancy of
insoluble pS202 has a more robust correlation with the
soluble pT217 rate than with Abeta42 concentration in
Abeta+ and AD brains, suggesting that tau phosphorylation is more associated with tau aggregation than
Abeta (Fig. 7). With continued increase of soluble pT217,
insoluble pS202 reaches a plateau possibly due to the
maturation of rigid NFTs composed of the most stable
conformation involving specific p-tau species.
Additionally, we found variability in phosphorylation
patterns for soluble pT111, pT153, and pT217 in the two
Abeta+ cases in the first cohort (#3 and #4; Additional
file 1: Fig. S10). Interestingly, #4 (Thal Abeta phase 3)
showed global increases of the phosphorylation rates
regardless of brain regions including cerebellum, and #3
(Thal Abeta phase 4) showed no changes in tau phosphorylation. It may be relevant that Abeta42 values in
#4 were much higher in the temporal lobe and amygdala
than in #3 (Fig. 1). These findings suggest that distribution of parenchymal Abeta plaques within the brain may
not be completely predictive of increased p-tau status
across brain regions during preclinical stages.

b

pT111 (0N)

Control

P‑tau species are modulated in brains with Abeta
pathology and modest NFT pathology

a

Phosphorylaon %

the second cohort also confirmed the results in the first
cohort (Additional file 1: Fig. S8). Of note, we did not
observe any relationships between ApoE genotypes and
Abeta42 and each p-tau species in both insoluble and
soluble extracts in the second cohort (Additional file 1:
Figs. S7, S8). There were no statistical differences in postmortem interval (PMI) in AD (n = 12) and control groups
(n = 8). PMI did not affect phosphorylation occupancies
or Abeta (data not shown).
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Fig. 6 Phosphorylation occupancies of soluble pT111, pT153,
and pT217 increase in AD, but pT181 does not in the first cohort.
Phosphorylation occupancies at residue a T111 (0N), b T153, and
c T217 in brain soluble extracts show staged increases in brains
with Abeta pathology and with minimal tau pathology (Abeta+).
Occupancies are further elevated in AD cases, in which both Abeta
and tau pathology are present. d The phosphorylation occupancy
of pT181 was approximately 10% in control brains with no clear
modulation due to amyloid and/or tau pathologies. Each bar shows
the mean ± SEM of two participants from each group

Discussion
We used biochemical fractionation and MS methods
to identify and quantify p-tau species and Abeta in AD
brains with various amounts of Abeta and NFT pathologies. We demonstrated that AD brain homogenate,
compared to controls, contained substantial amounts of
total Abeta42 together with soluble p-tau species, such
as pT111, pT153, pT205, pS208 and pT217. Importantly,
these sites were also hyperphosphorylated in CSF tau
from individuals with brain amyloidosis [2, 3], suggesting
high translatability of soluble brain p-tau profile to CSF.
We found that the extent of phosphorylation at these
sites in the soluble fraction linearly associated with local
Abeta, raising the possibility of a direct interplay between
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Fig. 7 Phosphorylation occupancies of insoluble pS202 correlate more with soluble pT217 phosphorylation rates, than Abeta42. a Phosphorylation
occupancy at T217 in brain soluble extracts showed a non-linear correlation (i.e., exponential-plateau) with pS202 in insoluble extracts ( R2 = 0.81
plateauing at 51%). b Abeta 42 did not correlate with pS202% in insoluble extracts from Abeta+ brain samples ( R2 = 0.51 plateauing at 50%). A total
of 28 brain soluble- and insoluble-matched extracts were analyzed from two Abeta+ brains (regions: CB, SFG, Temp, Ocp, Amy, Pari, and Striatum
from one case; CB, SFG, Temp, Ocp, Amy, Pari, and Striatum from the other participant) and two AD participants (regions: SFG, Temp, Ocp, Amy, Pari,
and Striatum from one participant; CB, SFG, Temp, Ocp, Amy, Pons, Pari, and Striatum from the other case). Regression curves depict an exponential
plateau model. Red squares and blue circles are individual data from AD and Abeta brains, respectively. Open data points indicate the data from CB
regions containing low amyloid pathology

Abeta and soluble p-tau. Notably, phosphorylation occupancy on pT217 had the best association with Abeta
amongst all the investigated sites, consistent with the
previously described excellent correlation between amyloid PET and CSF pT217 [1, 2]. Such association would
rationalize the tighter association observed between
amyloid marker and CSF pT217 over other sites such as
pT181. This would also support that CSF tau phosphorylation reflects soluble tau phosphorylation changes within
the brain in response to increased Abeta.
We also showed that insoluble tau was phosphorylated to a much higher extent than soluble tau, especially proximal to the proline-rich region of the tau mid
domain. This may support a cumulative enrichment of
corresponding p-tau species in tau that form aggregates.
Alternatively, tau hyperphosphorylated sites could be
inaccessible to brain phosphatase due to particular tau
conformation within NFTs. However, our data showing
bimodal correlation between insoluble tau and Abeta
would support the former. Indeed, in CSF, tau phosphorylation occupancies rapidly increase before saturating
at high Abeta load, suggesting a transitional change of
tau phosphorylation in parallel to Abeta deposition until
reaching a final hyperphosphorylation state in mature tau
aggregates. In contrast, MTBR-tau peptides that form the
cores of tau aggregates in AD brains were less directly
associated with Abeta, suggesting a distinct manner of
aggregation and recruitment into NFTs between MTBRtau and p-tau.

Interestingly, there was a different stoichiometry for
each p-tau to be in insoluble versus soluble fraction, suggesting its propensity to be sequestered into tau aggregates. pS202 and pT231 were particularly enriched in
insoluble fraction with phosphorylation occupancy
ranging from 60 to 80% and showed lower phosphorylation occupancy in AD soluble tau, suggesting that
pS202 and pT231 have higher propensity to be sequestered into insoluble tau. Consistently, pS202 is not found
hyperphosphorylated in AD CSF and even decreases
with symptoms [2, 3]. In contrast, in this study, pT217
phosphorylation occupancy was at approximately 30%
in insoluble AD brain extracts which corresponds to an
enrichment factor of about 50 times compared to soluble
tau. However, significant hyperphosphorylation of T217
found in AD soluble brain extract and CSF tau would
suggest only partial sequestration of this species into tau
aggregates. T111, T205 and S262 may have similar stoichiometries. Notably, pS262 has been described as protective against tau self-aggregation [27]. However, the
significant enrichment of pS262 in tau aggregates would
go against such protective role. pS285, on the other hand,
may be more likely to serve a protective role against
aggregation as it was only detected in AD soluble tau.
Additionally, we identified multiply-phosphorylated
tau species involving residues 198-199-202-205-208 in
AD brain homogenates. These species are linked to the
specific emergence of pT205 and pS208 in AD brain,
that form the epitope that is recognized by the AT8
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antibody [22], widely used in neuropathology to detect
tau aggregates. Interestingly, some of these sites were
also described as necessary to promote tau self-aggregation [7]. Our results would support the presence of such
highly phosphorylated tau species in AD brain.
The associations between local Abeta42 and multiple
soluble p-tau species shown in this study support the
amyloid hypothesis; however, causality between Abeta
and tau phosphorylation still needs to be addressed in
future studies. Hyperphosphorylation of soluble tau may
be mediated by specific kinases, reduced activity of phosphatases or result from synaptotoxicity, which may be
induced by Abeta, as previously described in vitro, and in
cell culture and animal models [11, 15, 30, 31]. The current study is also limited to measuring Abeta42 by MS
in brain homogenate as a surrogate of Abeta pathology;
this homogenate may contain a subset of soluble Abeta
monomers, dimers and oligomers, and insoluble Abeta
from Abeta plaques (which are more readily measured
by immunohistochemistry) that became accessible to
immunoprecipitation after sonication and resuspension.
Potentially, only a subset of Abeta with a specific conformation may induce specific phosphorylation of soluble
tau in neuronal cells. This may take place several years
before tau aggregates followed by NFT formation [23].
Other limitations of this study include its use of a small
number of autopsy cases within the first cohort, and variability in local correlation between Abeta and p-tau especially in the two Abeta+ cases which have different ApoE
genotypes. Although we did not observe a particular
effect of ApoE genotypes on Abeta or p-tau in the second
cohort, this needs to be addressed in a larger cohort in a
future study. Regardless, neuropathological [4] and neuroimaging [5, 20] studies using PET ligands indicate only
partially overlapping spatial topologies between Abeta
plaques and NFTs. This disconnect raises questions about
whether local levels of the two proteins should be directly
related, especially during preclinical stages of AD. There
is growing evidence that AD pathology is strongly tied to
both structural [29] and functional [13] network connectivity properties in the brain [28, 32]. This suggests that
abnormal levels of tau phosphorylation may additionally
be regulated by the presence of pathological Abeta in distant but connected regions. Focal Abeta pathology in the
temporal region has been implicated in the spreading of
global tau pathology, and focal Abeta pathology in the
occipital region has been associated with limited spreading [28], consistent with case #4 and #3 in our study. PET
ligands also measure very specific aggregated forms of
the two proteins while our current results indicate that
the disease process is regulating multiple soluble and
insoluble tau isoforms. Biochemical assays of tissue provide a finer measure of biological processes occurring
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than neuroimaging but with comparatively limited spatial
resolution. Future work may expand the number of brain
areas sampled in an effort to elucidate the network level
relationships seen with neuroimaging.
Our study provides detailed quantitative mapping of
p-tau sites in AD brain and evidence that supports local
interplay between Abeta and soluble p-tau. These results
lay groundwork for understanding dynamic metabolism
of multiple p-tau species in the brain and how it translates to CSF, assisting us with the interpretation of the
changes in CSF p-tau,or potentially plasma p-tau, during
AD pathogenesis.

Supplementary information
Supplementary information accompanies this paper at https://doi.
org/10.1186/s40478-020-01019-z.
Additional file 1: Figure S1. Fractionation protocol for brain soluble and
insoluble extract. Brain homogenates before sarkosyl extraction were used
for total Abeta (insoluble + soluble) analyses (1) and soluble tau analyses
(2). After sarkosyl extraction, insoluble fractions were used for insoluble tau
analyses (3). Figure S2. Abeta does not correlate with MTBR-tau enrichment in AD brain insoluble extracts in the first cohort. A total of 15 brain
insoluble extracts from two participants (#5: blue, #6: red) were analyzed
from two AD brains (regions: CB, SFG, Temp, Ocp, Amy, Pari, and Striatum
from one case; CB, SFG, Temp, Ocp, Amy, Pons, Pari, and Striatum from
the other case). Open data points indicate data from cerebellum regions
containing low amyloid pathology. (A) MTBR-tau-243, (B) MTBR-tau-299,
and (C) MTBR-tau-354 in brain insoluble extracts showed no significant
linear correlations (Spearman r = –0.12, r = –0.15, and r = –0.03, respectively) with Abeta42, suggesting that increase of MTBR-tau in AD brain is
independent of Abeta pathology. However, two-phase correlations may
be present in the relationship between Abeta42 and MTBR-tau in AD brain
insoluble extracts, because samples from CB with less amyloid pathology
showed low levels of MTBR-tau species. (D) Heat map of MTBR-tau-354
normalized enrichment across brain regions shows that there are low
regional correlations with Abeta42 concentrations in Fig. 1. Gray: data
was not available. Figure S3. Two-phase distribution may be present in
the relationship between Abeta42 and MTBR-tau in AD brain insoluble
extracts in the second cohort. A total of 20 brain insoluble extracts from
parietal region were analyzed (n = 8 amyloid-negative (open-black), n = 12
AD). The plot colors indicate ApoE genotypes in AD brains (open-blue: ε2/
ε3, open-green: ε3/ε3, open-red: ε3/ε4, filled-red: ε4/ε4). ApoE genotypes
did not appear to affect the relationship between Abeta42 and MTBR-tau.
(A) MTBR-tau-243, (B) MTBR-tau-299, and (C) MTBR-tau-354 in brain insoluble extracts showed significant correlations (Spearman r = 0.70, r = 0.74,
and r = 0.76, respectively) with Abeta42, suggesting that increase of MTBRtau in AD brain associates with amyloid pathology in a non-linear fashion.
Presumably, once the Abeta42 level exceeded the threshold, MTBR-tau
qualitatively increased, and then the correlations were no longer observed
(or plateaued) in AD brain samples with high Abeta42 levels. Figure S4.
Heat map of tau phosphorylation occupancies across different brain
regions in the first cohort. Nine to eleven brain regions from six participants with different stages of ADNC (NIA-AA stages A0-A3 for amyloid
deposition derived from Thal Abeta phases 0-5, and stages B0-B3 for Braak
NFT stages 0-VI) were analyzed for tau phosphorylation occupancies at
different sites. The data below limit of quantification are described as
“ND”. Gray: data was not available. Data for insoluble pT217 (A), insoluble
pT231 (B), soluble pT217 (C), and soluble pT231(D) are shown. Only tau
phosphorylation occupancy in soluble pT217 (C) locally correlated with
Abeta42 (described in Fig. 1). Figure S5. LC–MS/MS characterization of
phosphorylated SGYSSPGSPGTPR (195-210) peptide from AD brain soluble
fraction. (A) Mono phosphorylated peptides showing phosphorylation at
residues S199, S202, T205 and S208. (B) Doubly phosphorylated peptides
showing 10 combinations of phosphorylation involving residues S198,
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S199, S202, T205 and S208. (C) Triply phosphorylated peptides with undetermined position but at least involving pT205 + pS208. Figure S6. Doubly
phosphorylated tau peptides from AD brain soluble fraction involving
T205 and S208 disappeared after precipitation using sarkosyl extraction.
MS profile of doubly phosphorylated soluble tau peptides before (A) and
after (B) ultracentrifugation. The resulting soluble tau profile is similar to
the profile observed in AD brain [3]. Figure S7. Phosphorylation occupancies of insoluble pT181, pT217, and pT231 have significant correlations
with Abeta42 concentrations in AD brain from the second cohort. A total
of 20 brain insoluble extracts from parietal region were analyzed (n = 8
amyloid-negative (open-black), n = 12 AD). The plot colors indicate ApoE
genotypes in AD brains (open-blue: ε2/ε3, open-green: ε3/ε3, open-red:
ε3/ε4, filled-red: ε4/ε4). ApoE genotypes did not appear to affect the
relationship between Abeta42 and each p-tau in insoluble extracts. The
phosphorylation percentages of (A) pT181, (C) pT217, and (D) pT231 in
brain insoluble extracts showed significant correlations with Abeta42
concentrations (Spearman r = 0.68, r = 0.68, and r = 0.69, respectively).
On the other hand, the phosphorylation percentage of (B) pS202 in brain
insoluble extracts did not show any correlation with Abeta42 concentrations (Spearman r = 0.14), compared to the first cohort (Fig. 4. Figure
S8. Phosphorylation occupancies of select soluble p-tau are significantly
correlated with Abeta42 concentrations in AD brain from the second
cohort. A total of 20 brain insoluble extracts from parietal region were
analyzed (n = 8 amyloid-negative (open-black), n = 12 AD). The plot colors
indicate ApoE genotypes in AD brains (open-blue: ε2/ε3, open-green:
ε3/ε3, open-red: ε3/ε4, filled-red: ε4/ε4). ApoE genotypes did not affect
the relationship between Abeta42 and each p-tau in soluble extracts.
The phosphorylation occupancies of (A) pT111 (0N), (B) pT153, and (E)
pT217 in brain soluble extracts showed significant correlations with
soluble Abeta42 (Spearman r = 0.59, r = 0.71, and r = 0.61, respectively).
Phosphorylation at (C) pT181, (D) pS202 and (F) pT231 were less correlated
with Abeta42 (Spearman r = 0.36, r = 0.29 and r = 0.42, respectively),
which are consistent with the results from the first cohort (Fig. 5). Figure
S9 Phosphorylation occupancies of soluble pT111, pT153, and pT217
increase in AD, but pT181 does not in the second cohort. A total of 20
brain insoluble extracts from parietal region were analyzed (n = 8 amyloidnegative (open-black), n = 5 very mild to moderate AD, n = 7 severe AD).
The plot colors indicate ApoE genotypes in AD brains (open-blue: ε2/ε3,
open-green: ε3/ε3, open-red: ε3/ε4, filled-red: ε4/ε4). ApoE genotypes did
not show the clear differentiation for phosphorylation occupancies. Phosphorylation occupancies at residue (A) T111 (0N), (B) T153, and (C) T217 in
brain soluble extracts from the second cohort showed staged increases
according to AD progression. Phosphorylation occupancies are further
elevated in severe AD cases, relative to very mild to moderate AD cases.
(D) The phosphorylation occupancy of pT181 was approximately 10% in
control brains with no clear modulation due to AD progression. These
results from the second cohort are consistent with those from the first
cohort (Fig. 6). Data are represented as the individual results (plots) and
the mean (bar). Statistical differences were assessed with one-way ANOVA
with multiple comparisons correction using Benjamini–Hochberg false
discovery rate (FDR) method with FDR set at 5%. Figure S10. Phosphorylation occupancies of soluble pT111, pT153, and pT217 increase in AD, but
pT181 does not. (Individual data from Fig. 6). Phosphorylation occupancies
at residue (A) T111 (0 N), (B) T153, (C) T217, and (D) T181 in brain soluble
extracts with individual data points for Fig. 6 are shown. White bars show
the mean results from control (#1 and #2), Abeta+ (#3 and #4), and AD
(#5 and #6) brains with individual data points representing different brain
regions. Open data points indicate data from CB regions containing low
Abeta pathology. Table S1. Summary of tau peptides analyzed in the
study and phosphorylation occupancies. Table S2. Sample demographics
and neuropathological annotations in second cohort.
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